Display Settings:

Format

Send to:

Choose Destination
    Clin Trials. 2005;2(4):340-51; discussion 352-8, 364-78.

    ASTIN: a Bayesian adaptive dose-response trial in acute stroke.

    Source

    Statistical Research and Consulting Centre, Pfizer Global Research and Development, Sandwich, Kent, UK. Andy.P.Grieve@Pfizer.Com

    Abstract

    Understanding the dose-response is critical for successful drug development. We describe an adaptive design to efficiently learn about the dose-response and the ED95. A dynamic termination rule allows for early discontinuation either for efficacy or futility. The design was deployed in ASTIN, a phase II proof-of-concept trial of the neuroprotectant, neutrophil inhibitory factor (NIF), in acute stroke. We discuss the learning from this trial.

    PMID:
    16281432
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for HighWire Press

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk